| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft vs Host Disease | 109 | 2025 | 630 | 21.170 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 53 | 2025 | 1200 | 7.220 |
Why?
|
| Bone Marrow Transplantation | 49 | 2023 | 612 | 6.510 |
Why?
|
| T-Lymphocytes | 32 | 2024 | 1743 | 5.100 |
Why?
|
| Dendritic Cells | 20 | 2019 | 448 | 4.210 |
Why?
|
| Transplantation, Homologous | 62 | 2024 | 652 | 4.080 |
Why?
|
| Histone Deacetylase Inhibitors | 9 | 2017 | 86 | 2.660 |
Why?
|
| Gastrointestinal Microbiome | 10 | 2025 | 811 | 2.440 |
Why?
|
| Intestines | 9 | 2025 | 604 | 2.290 |
Why?
|
| Transplantation Conditioning | 17 | 2024 | 304 | 2.270 |
Why?
|
| Graft vs Leukemia Effect | 8 | 2020 | 36 | 2.150 |
Why?
|
| Mice, Inbred BALB C | 29 | 2024 | 1046 | 2.100 |
Why?
|
| Mice, Inbred C57BL | 45 | 2025 | 4754 | 1.980 |
Why?
|
| MicroRNAs | 8 | 2019 | 917 | 1.900 |
Why?
|
| Mice | 72 | 2025 | 18466 | 1.830 |
Why?
|
| Animals | 93 | 2025 | 34798 | 1.830 |
Why?
|
| Inflammation | 11 | 2025 | 1519 | 1.800 |
Why?
|
| Hydroxamic Acids | 5 | 2017 | 60 | 1.670 |
Why?
|
| Hematologic Neoplasms | 8 | 2024 | 295 | 1.660 |
Why?
|
| T-Lymphocytes, Regulatory | 9 | 2016 | 228 | 1.650 |
Why?
|
| Colitis | 4 | 2021 | 165 | 1.620 |
Why?
|
| Fatty Acids, Volatile | 4 | 2020 | 46 | 1.490 |
Why?
|
| Cytokines | 18 | 2020 | 1359 | 1.450 |
Why?
|
| Antigen-Presenting Cells | 11 | 2014 | 133 | 1.390 |
Why?
|
| STAT3 Transcription Factor | 5 | 2017 | 233 | 1.330 |
Why?
|
| RNA, Long Noncoding | 3 | 2022 | 240 | 1.280 |
Why?
|
| Stem Cells | 2 | 2025 | 732 | 1.280 |
Why?
|
| Acute Disease | 32 | 2020 | 1160 | 1.270 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2021 | 573 | 1.260 |
Why?
|
| Metabolome | 3 | 2025 | 325 | 1.180 |
Why?
|
| R-SNARE Proteins | 2 | 2019 | 11 | 1.160 |
Why?
|
| Graft vs Tumor Effect | 3 | 2020 | 8 | 1.160 |
Why?
|
| Autoimmunity | 2 | 2021 | 182 | 1.110 |
Why?
|
| Isoantigens | 7 | 2018 | 24 | 1.090 |
Why?
|
| Interleukin-10 | 3 | 2016 | 187 | 1.080 |
Why?
|
| Epithelial Cells | 4 | 2024 | 903 | 1.050 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2016 | 361 | 1.040 |
Why?
|
| Interleukin-6 | 4 | 2015 | 433 | 1.030 |
Why?
|
| Mitochondria | 3 | 2021 | 747 | 1.020 |
Why?
|
| Interleukin-18 | 5 | 2004 | 68 | 1.010 |
Why?
|
| Immune Tolerance | 2 | 2017 | 154 | 0.970 |
Why?
|
| Mice, Knockout | 18 | 2021 | 3861 | 0.970 |
Why?
|
| Tacrolimus | 3 | 2017 | 104 | 0.930 |
Why?
|
| Hematologic Diseases | 2 | 2025 | 82 | 0.910 |
Why?
|
| alpha 1-Antitrypsin | 2 | 2018 | 83 | 0.900 |
Why?
|
| Gene Expression Regulation | 10 | 2022 | 2438 | 0.880 |
Why?
|
| CD8 Antigens | 4 | 2015 | 44 | 0.880 |
Why?
|
| T-Lymphocyte Subsets | 8 | 2014 | 208 | 0.860 |
Why?
|
| Immunosuppressive Agents | 7 | 2015 | 672 | 0.860 |
Why?
|
| Immunologic Memory | 1 | 2025 | 197 | 0.850 |
Why?
|
| Oxidative Phosphorylation | 3 | 2021 | 124 | 0.830 |
Why?
|
| Antigen Presentation | 5 | 2017 | 117 | 0.820 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 4 | 2014 | 22 | 0.790 |
Why?
|
| Endoplasmic Reticulum | 2 | 2021 | 220 | 0.780 |
Why?
|
| Humans | 94 | 2025 | 132089 | 0.770 |
Why?
|
| Cells, Cultured | 12 | 2021 | 3037 | 0.770 |
Why?
|
| Lymphocyte Activation | 13 | 2020 | 679 | 0.770 |
Why?
|
| Epigenesis, Genetic | 2 | 2025 | 754 | 0.770 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2021 | 265 | 0.750 |
Why?
|
| Colon | 3 | 2021 | 370 | 0.750 |
Why?
|
| Bacteria | 2 | 2019 | 523 | 0.740 |
Why?
|
| Electron Transport Complex II | 1 | 2021 | 2 | 0.730 |
Why?
|
| Immunity, Cellular | 5 | 2017 | 201 | 0.730 |
Why?
|
| Vulnerable Populations | 1 | 2023 | 147 | 0.730 |
Why?
|
| Immune System Diseases | 1 | 2022 | 52 | 0.720 |
Why?
|
| Female | 71 | 2025 | 70695 | 0.710 |
Why?
|
| Gastrointestinal Diseases | 2 | 2023 | 357 | 0.700 |
Why?
|
| Histone Deacetylases | 4 | 2016 | 122 | 0.690 |
Why?
|
| COP-Coated Vesicles | 1 | 2021 | 5 | 0.690 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2020 | 15 | 0.690 |
Why?
|
| Disease Models, Animal | 19 | 2024 | 4685 | 0.690 |
Why?
|
| Golgi Apparatus | 1 | 2021 | 95 | 0.670 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2024 | 305 | 0.670 |
Why?
|
| Hematology | 1 | 2020 | 41 | 0.660 |
Why?
|
| Lipopolysaccharides | 6 | 2019 | 306 | 0.640 |
Why?
|
| Cell Differentiation | 6 | 2024 | 1960 | 0.640 |
Why?
|
| Methotrexate | 2 | 2024 | 350 | 0.640 |
Why?
|
| Hematopoietic System | 1 | 2019 | 6 | 0.630 |
Why?
|
| Mice, Inbred C3H | 6 | 2019 | 118 | 0.620 |
Why?
|
| Th2 Cells | 3 | 2011 | 188 | 0.610 |
Why?
|
| Receptors, Cell Surface | 2 | 2019 | 450 | 0.600 |
Why?
|
| Sirtuin 3 | 1 | 2018 | 30 | 0.580 |
Why?
|
| Signal Transduction | 11 | 2019 | 4704 | 0.580 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2023 | 898 | 0.570 |
Why?
|
| Unrelated Donors | 2 | 2018 | 70 | 0.570 |
Why?
|
| Histocompatibility | 3 | 2021 | 42 | 0.550 |
Why?
|
| Endothelial Cells | 2 | 2019 | 527 | 0.550 |
Why?
|
| Embryonic Development | 1 | 2019 | 215 | 0.550 |
Why?
|
| RNA, Untranslated | 1 | 2018 | 112 | 0.550 |
Why?
|
| CD8-Positive T-Lymphocytes | 9 | 2018 | 442 | 0.540 |
Why?
|
| Steroids | 1 | 2018 | 173 | 0.540 |
Why?
|
| Intestinal Mucosa | 2 | 2021 | 794 | 0.540 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2018 | 131 | 0.530 |
Why?
|
| Allografts | 10 | 2019 | 195 | 0.530 |
Why?
|
| Receptors, Interleukin-10 | 1 | 2016 | 3 | 0.520 |
Why?
|
| Myeloid Cells | 1 | 2017 | 116 | 0.510 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 493 | 0.500 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 396 | 0.490 |
Why?
|
| T-Lymphocytes, Cytotoxic | 5 | 2018 | 519 | 0.480 |
Why?
|
| Peer Review, Research | 1 | 2016 | 44 | 0.480 |
Why?
|
| Butyrates | 3 | 2023 | 42 | 0.470 |
Why?
|
| Transplantation Immunology | 3 | 2016 | 45 | 0.470 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2025 | 550 | 0.470 |
Why?
|
| Survival Rate | 16 | 2019 | 2194 | 0.470 |
Why?
|
| Models, Biological | 2 | 2018 | 1443 | 0.460 |
Why?
|
| Trans-Activators | 2 | 2013 | 712 | 0.450 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2015 | 34 | 0.450 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2017 | 216 | 0.450 |
Why?
|
| Immunotherapy | 2 | 2017 | 745 | 0.440 |
Why?
|
| Biomarkers | 13 | 2019 | 3407 | 0.440 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2013 | 488 | 0.440 |
Why?
|
| Dysbiosis | 3 | 2025 | 140 | 0.440 |
Why?
|
| Busulfan | 3 | 2015 | 44 | 0.440 |
Why?
|
| Boronic Acids | 1 | 2014 | 47 | 0.440 |
Why?
|
| Receptor, Notch1 | 2 | 2013 | 76 | 0.440 |
Why?
|
| CD24 Antigen | 1 | 2014 | 33 | 0.430 |
Why?
|
| Acetylation | 4 | 2017 | 191 | 0.430 |
Why?
|
| Immune System | 3 | 2022 | 97 | 0.430 |
Why?
|
| Lectins | 1 | 2014 | 49 | 0.430 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2014 | 33 | 0.430 |
Why?
|
| Pyrazines | 1 | 2014 | 72 | 0.430 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2016 | 153 | 0.420 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2014 | 48 | 0.420 |
Why?
|
| Carrier Proteins | 2 | 2016 | 1047 | 0.410 |
Why?
|
| Mycophenolic Acid | 1 | 2013 | 57 | 0.410 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 3 | 2019 | 29 | 0.410 |
Why?
|
| Ubiquitins | 1 | 2013 | 43 | 0.410 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2019 | 1044 | 0.400 |
Why?
|
| Leukemia | 5 | 2013 | 370 | 0.390 |
Why?
|
| Adult | 31 | 2025 | 31575 | 0.390 |
Why?
|
| Hematopoiesis | 2 | 2011 | 224 | 0.390 |
Why?
|
| Flow Cytometry | 5 | 2019 | 791 | 0.390 |
Why?
|
| Models, Animal | 3 | 2018 | 469 | 0.380 |
Why?
|
| Mice, Transgenic | 6 | 2021 | 2444 | 0.380 |
Why?
|
| Middle Aged | 33 | 2025 | 28998 | 0.370 |
Why?
|
| H-Y Antigen | 1 | 2011 | 1 | 0.370 |
Why?
|
| Tissue Donors | 6 | 2018 | 504 | 0.370 |
Why?
|
| Leukocyte Transfusion | 1 | 2011 | 7 | 0.370 |
Why?
|
| Pancreatitis-Associated Proteins | 5 | 2018 | 14 | 0.360 |
Why?
|
| Basophils | 1 | 2011 | 13 | 0.360 |
Why?
|
| Adaptation, Physiological | 1 | 2013 | 271 | 0.360 |
Why?
|
| Recurrence | 6 | 2021 | 1469 | 0.350 |
Why?
|
| Ikaros Transcription Factor | 1 | 2011 | 32 | 0.350 |
Why?
|
| Cell Proliferation | 7 | 2021 | 2508 | 0.350 |
Why?
|
| Inflammation Mediators | 3 | 2013 | 240 | 0.340 |
Why?
|
| Toll-Like Receptor 4 | 3 | 2019 | 140 | 0.340 |
Why?
|
| Microbiota | 3 | 2025 | 434 | 0.340 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 5 | 2017 | 51 | 0.340 |
Why?
|
| Immunity, Innate | 3 | 2019 | 413 | 0.330 |
Why?
|
| Male | 39 | 2025 | 64967 | 0.320 |
Why?
|
| Graft Survival | 4 | 2014 | 474 | 0.320 |
Why?
|
| Apoptosis | 6 | 2018 | 1892 | 0.320 |
Why?
|
| Hepatitis B | 1 | 2011 | 172 | 0.310 |
Why?
|
| Survival Analysis | 6 | 2017 | 1573 | 0.310 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 613 | 0.300 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 3 | 2018 | 23 | 0.300 |
Why?
|
| Cell Communication | 3 | 2021 | 187 | 0.300 |
Why?
|
| Enzyme Inhibitors | 2 | 2009 | 589 | 0.290 |
Why?
|
| Kidney Transplantation | 2 | 2011 | 570 | 0.290 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 1280 | 0.290 |
Why?
|
| Sepsis | 2 | 2011 | 515 | 0.290 |
Why?
|
| Histones | 3 | 2017 | 534 | 0.280 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 1422 | 0.280 |
Why?
|
| Aged | 22 | 2020 | 21438 | 0.280 |
Why?
|
| Feasibility Studies | 2 | 2023 | 824 | 0.280 |
Why?
|
| Feces | 3 | 2024 | 756 | 0.270 |
Why?
|
| Myeloablative Agonists | 3 | 2015 | 20 | 0.270 |
Why?
|
| Semaphorins | 1 | 2007 | 33 | 0.270 |
Why?
|
| RNA, Messenger | 1 | 2013 | 2674 | 0.270 |
Why?
|
| Disease-Free Survival | 7 | 2019 | 959 | 0.270 |
Why?
|
| Interleukins | 1 | 2008 | 129 | 0.260 |
Why?
|
| Immunoglobulin G | 4 | 2014 | 806 | 0.260 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 1826 | 0.260 |
Why?
|
| Up-Regulation | 3 | 2015 | 876 | 0.260 |
Why?
|
| Receptors, Tumor Necrosis Factor | 4 | 2014 | 77 | 0.260 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2555 | 0.260 |
Why?
|
| Lymphopenia | 1 | 2007 | 39 | 0.260 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 1882 | 0.260 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2012 | 822 | 0.240 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2018 | 142 | 0.240 |
Why?
|
| Gene Expression | 4 | 2016 | 1558 | 0.230 |
Why?
|
| Photochemotherapy | 1 | 2005 | 41 | 0.230 |
Why?
|
| Stomatitis | 1 | 2025 | 17 | 0.230 |
Why?
|
| Transcription Factors | 1 | 2015 | 2493 | 0.230 |
Why?
|
| Cyclopentanes | 2 | 2016 | 21 | 0.230 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2018 | 379 | 0.220 |
Why?
|
| Multiple Myeloma | 2 | 2019 | 204 | 0.220 |
Why?
|
| Immunophenotyping | 2 | 2018 | 343 | 0.220 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 2018 | 25 | 0.220 |
Why?
|
| Mouth | 1 | 2025 | 67 | 0.220 |
Why?
|
| Bacteroides | 1 | 2024 | 37 | 0.220 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 4 | 2017 | 33 | 0.210 |
Why?
|
| Lymphocyte Depletion | 2 | 2019 | 125 | 0.210 |
Why?
|
| Homeostasis | 2 | 2019 | 722 | 0.210 |
Why?
|
| Minor Histocompatibility Antigens | 2 | 2018 | 39 | 0.210 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 420 | 0.210 |
Why?
|
| Th1 Cells | 1 | 2004 | 156 | 0.210 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2005 | 169 | 0.210 |
Why?
|
| B-Lymphocytes | 4 | 2016 | 540 | 0.210 |
Why?
|
| Genomic Imprinting | 1 | 2024 | 130 | 0.210 |
Why?
|
| Regeneration | 2 | 2024 | 226 | 0.210 |
Why?
|
| Peroxidase | 2 | 2020 | 63 | 0.200 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2023 | 32 | 0.200 |
Why?
|
| NF-kappa B | 3 | 2015 | 455 | 0.200 |
Why?
|
| Etanercept | 5 | 2015 | 47 | 0.200 |
Why?
|
| Organ Specificity | 3 | 2017 | 412 | 0.200 |
Why?
|
| Mastocytoma | 1 | 2002 | 1 | 0.200 |
Why?
|
| Medically Underserved Area | 1 | 2023 | 92 | 0.200 |
Why?
|
| HLA Antigens | 3 | 2016 | 218 | 0.200 |
Why?
|
| Chronic Disease | 6 | 2025 | 1234 | 0.200 |
Why?
|
| Adolescent | 20 | 2020 | 20560 | 0.190 |
Why?
|
| Photopheresis | 2 | 2015 | 4 | 0.190 |
Why?
|
| Quinone Reductases | 1 | 2021 | 3 | 0.190 |
Why?
|
| Hydrogen Sulfide | 1 | 2021 | 13 | 0.180 |
Why?
|
| Succinic Acid | 1 | 2021 | 13 | 0.180 |
Why?
|
| Pyrimidines | 2 | 2016 | 418 | 0.180 |
Why?
|
| Minority Groups | 1 | 2023 | 249 | 0.180 |
Why?
|
| Lectins, C-Type | 2 | 2012 | 70 | 0.180 |
Why?
|
| Prospective Studies | 7 | 2018 | 6572 | 0.180 |
Why?
|
| Histocompatibility Testing | 4 | 2016 | 110 | 0.180 |
Why?
|
| Paneth Cells | 2 | 2018 | 26 | 0.180 |
Why?
|
| Immunity, Mucosal | 1 | 2021 | 94 | 0.180 |
Why?
|
| Organoids | 1 | 2024 | 300 | 0.180 |
Why?
|
| Protein Binding | 2 | 2016 | 1730 | 0.180 |
Why?
|
| Immunoprecipitation | 2 | 2013 | 196 | 0.170 |
Why?
|
| Biological Transport, Active | 1 | 2021 | 76 | 0.170 |
Why?
|
| Neutropenia | 1 | 2022 | 205 | 0.170 |
Why?
|
| Mammals | 1 | 2022 | 272 | 0.170 |
Why?
|
| Mice, Mutant Strains | 2 | 2011 | 378 | 0.170 |
Why?
|
| Erythropoiesis | 1 | 2020 | 37 | 0.170 |
Why?
|
| Young Adult | 10 | 2020 | 9958 | 0.170 |
Why?
|
| Cell Line | 3 | 2019 | 2719 | 0.170 |
Why?
|
| Spleen | 3 | 2019 | 270 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 1284 | 0.160 |
Why?
|
| Forkhead Transcription Factors | 2 | 2014 | 381 | 0.160 |
Why?
|
| Interferon-alpha | 1 | 2021 | 246 | 0.160 |
Why?
|
| Histocompatibility Antigens Class II | 4 | 2010 | 84 | 0.160 |
Why?
|
| Erythropoietin | 1 | 2020 | 107 | 0.160 |
Why?
|
| Severity of Illness Index | 4 | 2014 | 3092 | 0.160 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2019 | 26 | 0.150 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2019 | 37 | 0.150 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2019 | 60 | 0.150 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 22 | 0.150 |
Why?
|
| Antigens, Neoplasm | 2 | 2012 | 401 | 0.150 |
Why?
|
| Endotoxins | 1 | 2019 | 48 | 0.150 |
Why?
|
| Bone Marrow | 1 | 2020 | 327 | 0.150 |
Why?
|
| Genome, Mitochondrial | 1 | 2019 | 33 | 0.150 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2018 | 15 | 0.150 |
Why?
|
| Glucocorticoids | 2 | 2014 | 386 | 0.150 |
Why?
|
| Stem Cell Transplantation | 2 | 2015 | 249 | 0.140 |
Why?
|
| Glycolysis | 1 | 2019 | 166 | 0.140 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2018 | 9 | 0.140 |
Why?
|
| Interferon-gamma | 7 | 2015 | 534 | 0.140 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 133 | 0.140 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2018 | 33 | 0.140 |
Why?
|
| Macrophages | 2 | 2020 | 689 | 0.140 |
Why?
|
| Membrane Proteins | 3 | 2020 | 1610 | 0.140 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2024 | 162 | 0.140 |
Why?
|
| NIH 3T3 Cells | 2 | 2019 | 95 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2019 | 362 | 0.140 |
Why?
|
| Cross-Priming | 1 | 2017 | 5 | 0.140 |
Why?
|
| Mice, Inbred DBA | 2 | 2010 | 56 | 0.130 |
Why?
|
| Risk Factors | 10 | 2017 | 10946 | 0.130 |
Why?
|
| Primary Cell Culture | 2 | 2018 | 107 | 0.130 |
Why?
|
| Bone Marrow Cells | 2 | 2016 | 258 | 0.130 |
Why?
|
| Embryo, Mammalian | 1 | 2019 | 440 | 0.130 |
Why?
|
| Drug Resistance | 1 | 2018 | 252 | 0.130 |
Why?
|
| Cellular Microenvironment | 1 | 2017 | 10 | 0.130 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 162 | 0.130 |
Why?
|
| Interleukin-15 | 1 | 2018 | 95 | 0.130 |
Why?
|
| Physicians | 1 | 2024 | 642 | 0.130 |
Why?
|
| Models, Immunological | 1 | 2017 | 37 | 0.130 |
Why?
|
| Protein Transport | 2 | 2020 | 369 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1305 | 0.130 |
Why?
|
| Neuroprotective Agents | 1 | 2018 | 161 | 0.130 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 394 | 0.130 |
Why?
|
| Lymphocyte Count | 2 | 2014 | 119 | 0.130 |
Why?
|
| Incidence | 2 | 2017 | 3379 | 0.130 |
Why?
|
| Fatty Acids | 1 | 2019 | 356 | 0.130 |
Why?
|
| Demography | 1 | 2017 | 241 | 0.130 |
Why?
|
| Inflammasomes | 1 | 2018 | 167 | 0.130 |
Why?
|
| Adaptive Immunity | 1 | 2017 | 95 | 0.130 |
Why?
|
| Neutrophils | 1 | 2018 | 361 | 0.130 |
Why?
|
| RNA Interference | 1 | 2018 | 514 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 672 | 0.120 |
Why?
|
| Methylprednisolone | 2 | 2007 | 98 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 3 | 2010 | 1028 | 0.120 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2016 | 67 | 0.120 |
Why?
|
| Microarray Analysis | 1 | 2016 | 236 | 0.120 |
Why?
|
| Ubiquitination | 1 | 2016 | 172 | 0.120 |
Why?
|
| E2F7 Transcription Factor | 1 | 2015 | 1 | 0.120 |
Why?
|
| Chemokines | 1 | 2016 | 129 | 0.120 |
Why?
|
| Immunoblotting | 1 | 2016 | 301 | 0.120 |
Why?
|
| United States | 4 | 2024 | 11667 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 339 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2013 | 200 | 0.120 |
Why?
|
| Transplant Recipients | 1 | 2017 | 225 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 1548 | 0.120 |
Why?
|
| Transplantation, Autologous | 1 | 2016 | 286 | 0.120 |
Why?
|
| Stomach Diseases | 1 | 2015 | 56 | 0.120 |
Why?
|
| Histone Acetyltransferases | 1 | 2016 | 227 | 0.120 |
Why?
|
| Enzyme Activation | 2 | 2013 | 615 | 0.120 |
Why?
|
| Vidarabine | 1 | 2015 | 82 | 0.110 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2014 | 26 | 0.110 |
Why?
|
| Intestinal Diseases | 1 | 2015 | 76 | 0.110 |
Why?
|
| Leukocyte Common Antigens | 1 | 2014 | 88 | 0.110 |
Why?
|
| Glucose | 1 | 2019 | 870 | 0.110 |
Why?
|
| Leukemia, Experimental | 2 | 2005 | 16 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 553 | 0.110 |
Why?
|
| Cyclosporine | 1 | 2015 | 126 | 0.110 |
Why?
|
| Radiation | 1 | 2014 | 3 | 0.110 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2014 | 7 | 0.110 |
Why?
|
| Bortezomib | 1 | 2014 | 71 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2021 | 3416 | 0.110 |
Why?
|
| Genes, Transgenic, Suicide | 1 | 2014 | 48 | 0.110 |
Why?
|
| Haplotypes | 1 | 2016 | 544 | 0.110 |
Why?
|
| Calcineurin Inhibitors | 1 | 2014 | 27 | 0.110 |
Why?
|
| Acute Lung Injury | 1 | 2015 | 68 | 0.110 |
Why?
|
| Interleukin-17 | 1 | 2015 | 129 | 0.110 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2018 | 326 | 0.110 |
Why?
|
| In Vitro Techniques | 1 | 2015 | 862 | 0.110 |
Why?
|
| Argonaute Proteins | 1 | 2013 | 31 | 0.100 |
Why?
|
| Genome | 1 | 2016 | 504 | 0.100 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2013 | 4 | 0.100 |
Why?
|
| Thymectomy | 2 | 2011 | 23 | 0.100 |
Why?
|
| NEDD8 Protein | 1 | 2013 | 12 | 0.100 |
Why?
|
| Clinical Trials as Topic | 3 | 2014 | 1163 | 0.100 |
Why?
|
| I-kappa B Proteins | 1 | 2013 | 39 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 1538 | 0.100 |
Why?
|
| DNA | 1 | 2019 | 1473 | 0.100 |
Why?
|
| Receptor, Notch2 | 1 | 2013 | 12 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2012 | 1659 | 0.100 |
Why?
|
| Radiation Tolerance | 2 | 2011 | 64 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 354 | 0.100 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2013 | 100 | 0.100 |
Why?
|
| Cognition | 1 | 2018 | 811 | 0.100 |
Why?
|
| Cell Cycle | 1 | 2015 | 611 | 0.100 |
Why?
|
| Child, Preschool | 12 | 2018 | 14749 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2020 | 1008 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2013 | 3739 | 0.100 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2012 | 37 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 397 | 0.090 |
Why?
|
| Proteolysis | 1 | 2013 | 198 | 0.090 |
Why?
|
| Infant | 11 | 2018 | 13061 | 0.090 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2011 | 54 | 0.090 |
Why?
|
| Lymphoma | 2 | 2013 | 331 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 845 | 0.090 |
Why?
|
| Adenine Nucleotides | 1 | 2011 | 36 | 0.090 |
Why?
|
| Patient Participation | 1 | 2014 | 240 | 0.090 |
Why?
|
| Arabinonucleosides | 1 | 2011 | 33 | 0.090 |
Why?
|
| Retrospective Studies | 10 | 2019 | 17416 | 0.090 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2011 | 55 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 946 | 0.090 |
Why?
|
| Receptors, Notch | 1 | 2013 | 212 | 0.090 |
Why?
|
| CD11c Antigen | 1 | 2011 | 40 | 0.090 |
Why?
|
| Databases as Topic | 1 | 2011 | 76 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2013 | 677 | 0.080 |
Why?
|
| Remission Induction | 3 | 2019 | 307 | 0.080 |
Why?
|
| Mice, 129 Strain | 1 | 2010 | 100 | 0.080 |
Why?
|
| Transplantation Chimera | 3 | 2005 | 43 | 0.080 |
Why?
|
| 3' Untranslated Regions | 1 | 2011 | 166 | 0.080 |
Why?
|
| Mice, Inbred Strains | 2 | 2008 | 308 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2015 | 812 | 0.080 |
Why?
|
| Liver Failure | 1 | 2011 | 91 | 0.080 |
Why?
|
| Time Factors | 4 | 2019 | 6448 | 0.080 |
Why?
|
| Elafin | 1 | 2010 | 2 | 0.080 |
Why?
|
| Pancreas Transplantation | 1 | 2010 | 31 | 0.080 |
Why?
|
| Cell Separation | 1 | 2010 | 223 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 589 | 0.080 |
Why?
|
| Child | 13 | 2020 | 25786 | 0.080 |
Why?
|
| Genetic Therapy | 1 | 2014 | 719 | 0.080 |
Why?
|
| Drugs, Investigational | 1 | 2009 | 24 | 0.080 |
Why?
|
| Immunization, Passive | 1 | 2009 | 128 | 0.080 |
Why?
|
| Skin | 2 | 2010 | 527 | 0.070 |
Why?
|
| Radiation Chimera | 3 | 2003 | 18 | 0.070 |
Why?
|
| Autografts | 2 | 2019 | 29 | 0.070 |
Why?
|
| Graft vs Host Reaction | 1 | 2008 | 10 | 0.070 |
Why?
|
| Treatment Outcome | 7 | 2018 | 13034 | 0.070 |
Why?
|
| Immunologic Tests | 1 | 2008 | 17 | 0.070 |
Why?
|
| Major Histocompatibility Complex | 1 | 2008 | 53 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 1132 | 0.070 |
Why?
|
| Proteins | 1 | 2013 | 1035 | 0.070 |
Why?
|
| Tissue and Organ Procurement | 1 | 2011 | 246 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 900 | 0.070 |
Why?
|
| Neoplasms | 1 | 2022 | 2957 | 0.070 |
Why?
|
| Interleukin-8 | 1 | 2008 | 210 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 1131 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2020 | 799 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2014 | 1122 | 0.070 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2007 | 35 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 1460 | 0.070 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2004 | 105 | 0.070 |
Why?
|
| Lung | 1 | 2015 | 1559 | 0.070 |
Why?
|
| Blotting, Western | 1 | 2009 | 1077 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2009 | 305 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2005 | 664 | 0.060 |
Why?
|
| Pore Forming Cytotoxic Proteins | 2 | 2004 | 19 | 0.060 |
Why?
|
| Perforin | 2 | 2004 | 25 | 0.060 |
Why?
|
| Prognosis | 5 | 2018 | 5014 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2008 | 431 | 0.060 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 687 | 0.060 |
Why?
|
| Phenotype | 2 | 2013 | 4528 | 0.060 |
Why?
|
| Mice, SCID | 1 | 2007 | 601 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2011 | 822 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 313 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2005 | 32 | 0.060 |
Why?
|
| Bacteroides thetaiotaomicron | 1 | 2024 | 9 | 0.060 |
Why?
|
| Receptors, Interleukin-18 | 1 | 2004 | 1 | 0.060 |
Why?
|
| Interleukin-18 Receptor alpha Subunit | 1 | 2004 | 2 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 762 | 0.060 |
Why?
|
| Receptors, Interleukin | 1 | 2004 | 35 | 0.050 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2005 | 223 | 0.050 |
Why?
|
| Receptors, Chemokine | 1 | 2003 | 46 | 0.050 |
Why?
|
| Ontario | 1 | 2023 | 90 | 0.050 |
Why?
|
| Clonal Deletion | 1 | 2003 | 3 | 0.050 |
Why?
|
| Liver | 3 | 2012 | 1796 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 3681 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2024 | 151 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2022 | 15 | 0.050 |
Why?
|
| H-2 Antigens | 1 | 2002 | 26 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2003 | 100 | 0.050 |
Why?
|
| Propionates | 1 | 2022 | 33 | 0.050 |
Why?
|
| Mucus | 1 | 2022 | 36 | 0.050 |
Why?
|
| STAT6 Transcription Factor | 1 | 2002 | 32 | 0.050 |
Why?
|
| Mucins | 1 | 2022 | 71 | 0.050 |
Why?
|
| Career Choice | 1 | 2024 | 160 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2015 | 1179 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2002 | 136 | 0.050 |
Why?
|
| Neoplasm Transplantation | 1 | 2002 | 382 | 0.050 |
Why?
|
| Electron Transport Complex IV | 1 | 2021 | 41 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2023 | 244 | 0.050 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 255 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2021 | 47 | 0.040 |
Why?
|
| Epithelium | 1 | 2002 | 354 | 0.040 |
Why?
|
| Mutation | 1 | 2015 | 6228 | 0.040 |
Why?
|
| Algorithms | 2 | 2019 | 1722 | 0.040 |
Why?
|
| Quality of Life | 2 | 2023 | 2161 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2010 | 861 | 0.040 |
Why?
|
| Killer Cells, Natural | 2 | 2019 | 348 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 436 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 136 | 0.040 |
Why?
|
| Serum Amyloid A Protein | 1 | 2020 | 44 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2003 | 271 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2020 | 136 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 391 | 0.040 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2019 | 3 | 0.040 |
Why?
|
| Muromegalovirus | 1 | 2019 | 11 | 0.040 |
Why?
|
| Infant, Newborn | 4 | 2017 | 8549 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 779 | 0.040 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2019 | 25 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2020 | 178 | 0.040 |
Why?
|
| Gastrointestinal Tract | 2 | 2012 | 232 | 0.040 |
Why?
|
| Body Temperature | 1 | 2019 | 128 | 0.040 |
Why?
|
| Probability | 1 | 2019 | 322 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 1347 | 0.040 |
Why?
|
| Leukocyte Elastase | 1 | 2018 | 19 | 0.040 |
Why?
|
| Obesity | 1 | 2010 | 2395 | 0.040 |
Why?
|
| Tandem Repeat Sequences | 1 | 2018 | 36 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2010 | 3142 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2020 | 294 | 0.030 |
Why?
|
| Consensus | 1 | 2021 | 651 | 0.030 |
Why?
|
| Metabolomics | 1 | 2021 | 480 | 0.030 |
Why?
|
| Escherichia coli Infections | 1 | 2018 | 192 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 472 | 0.030 |
Why?
|
| Cellular Reprogramming | 1 | 2018 | 127 | 0.030 |
Why?
|
| Cell Survival | 1 | 2018 | 866 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1125 | 0.030 |
Why?
|
| Michigan | 1 | 2015 | 50 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 3766 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2015 | 113 | 0.030 |
Why?
|
| Salvage Therapy | 2 | 2009 | 200 | 0.030 |
Why?
|
| Aging | 1 | 2002 | 1248 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 2322 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2015 | 97 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 4003 | 0.030 |
Why?
|
| Dibenzazepines | 1 | 2013 | 3 | 0.030 |
Why?
|
| Focus Groups | 1 | 2014 | 224 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2018 | 995 | 0.020 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2013 | 58 | 0.020 |
Why?
|
| Adoptive Transfer | 2 | 2005 | 239 | 0.020 |
Why?
|
| Th1-Th2 Balance | 1 | 2012 | 8 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2013 | 238 | 0.020 |
Why?
|
| Interleukin-1 | 2 | 2003 | 135 | 0.020 |
Why?
|
| Keratin-18 | 1 | 2012 | 8 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2012 | 61 | 0.020 |
Why?
|
| T-Box Domain Proteins | 1 | 2013 | 122 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 174 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2013 | 333 | 0.020 |
Why?
|
| Antibodies | 1 | 2013 | 365 | 0.020 |
Why?
|
| Informed Consent | 1 | 2014 | 347 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 294 | 0.020 |
Why?
|
| Syndrome | 1 | 2014 | 1174 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 321 | 0.020 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2011 | 26 | 0.020 |
Why?
|
| Diarrhea | 1 | 2013 | 330 | 0.020 |
Why?
|
| Lactates | 1 | 2011 | 85 | 0.020 |
Why?
|
| Genomics | 1 | 2019 | 1647 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 749 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2011 | 109 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 573 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 2057 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 601 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2011 | 305 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5416 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 624 | 0.020 |
Why?
|
| Diabetic Nephropathies | 1 | 2010 | 115 | 0.020 |
Why?
|
| Risk | 1 | 2010 | 761 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2009 | 130 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1439 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 517 | 0.020 |
Why?
|
| Cause of Death | 1 | 2010 | 510 | 0.020 |
Why?
|
| Forecasting | 1 | 2009 | 371 | 0.020 |
Why?
|
| Proteomics | 1 | 2011 | 596 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 2669 | 0.020 |
Why?
|
| Overweight | 1 | 2010 | 383 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3770 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 803 | 0.010 |
Why?
|
| CD40 Ligand | 1 | 2005 | 64 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2004 | 36 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2014 | 5168 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 2004 | 58 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2005 | 319 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2010 | 1697 | 0.010 |
Why?
|
| Scleroderma, Diffuse | 1 | 2003 | 4 | 0.010 |
Why?
|
| Receptors, CXCR3 | 1 | 2003 | 22 | 0.010 |
Why?
|
| Xerophthalmia | 1 | 2003 | 8 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2003 | 40 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2003 | 63 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 2003 | 15 | 0.010 |
Why?
|
| Self Tolerance | 1 | 2003 | 6 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 285 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2003 | 81 | 0.010 |
Why?
|
| Acute-Phase Proteins | 1 | 2003 | 45 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2003 | 57 | 0.010 |
Why?
|
| Viscera | 1 | 2003 | 55 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 123 | 0.010 |
Why?
|
| Rituximab | 1 | 2003 | 168 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1342 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2002 | 235 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2005 | 1444 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 743 | 0.010 |
Why?
|
| Intestine, Small | 1 | 2002 | 309 | 0.010 |
Why?
|
| Cell Movement | 1 | 2003 | 889 | 0.010 |
Why?
|